Industry Update: Biotechnology
VRC is proud to release its latest industry report. The report provides a concise, insightful update on the Biotechnology industry including recent transactions, market multiples, company performance and purchase price allocation percentages.
- On October 28, 2020, Seagen Inc. (Seattle Genetics) closed on its billion dollar cancer development partnership with Merck Sharp & Dohme Corp. Seagen is eligible to receive progress-dependent milestone payments of up to $2.6 billion from the ladiratuzumab vedotin collaboration.
- On December 10, 2020, Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on the treatment of the chronic hepatitis delta virus, announced that the companies have entered a definitive agreement pursuant to which Gilead will acquire MYR for approximately $1.7 billion.
Past Industry Updates
More Industry Reports